Lymphoma Treatment Market
Segments - by Type (Hodgkin Lymphoma and Non-Hodgkin Lymphoma), Drug (Adcetris, Rituxan/MabThera, Imbruvica, Keytruda, Revlimid, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The global lymphoma treatment market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing demand for high-priced drugs such immune checkpoint inhibitors, Keytruda, and Opdivo.
Lymphoma is a type of cancer that affects the lymphatic system. Lymphocytes, a type of white blood cell, are where it develops. These cells aid in the battle against disease and play a crucial part in the body's immunological defenses. Lymphoma is caused by abnormal growth of B or T lymphocytes and leukocytes. It can also develop if these cells live longer than their typical lifespan. As this type of cancer is found in the lymphatic system, it can rapidly spread to other tissues and organs throughout the body. The liver, bone marrow, and lungs are the most common sites for lymphoma to spread. Lymphoma can affect anyone at any age, but it is one of the most frequent cancers in children and young adults aged 15 to 24 and it is usually curable. Hodgkin lymphoma and non-Hodgkin lymphoma are the two main types of lymphoma. Hodgkin lymphoma occurs in the lymphatic system's lymph nodes. Non-Hodgkin lymphoma is the most prevalent type of lymphoma, and it arises in lymphatic system and lymph node-related tissues. Lymphoma symptoms include lymph node swelling, fever, weight loss, nighttime sweets, anorexia, itching, dyspnea, and exhaustion. Immunophenotyping, FISH (Fluorescence in Situ Hybridization) testing, and flow cytometry are all frequent techniques used to diagnose lymphoma. Patients with lymphoma are treated with radiation therapy, chemotherapy, and monoclonal antibody therapy.
Chemotherapy is the most prevalent treatment for lymphoma among all of these alternatives. Chemotherapy is one of the most important methods for lymphoma treatment since it kills cancer cells by preventing them from dividing. During the course of treatment, these drugs travel throughout the body. Adcertis (brentuximab), Arranon (nelarabine), Adriamycin (doxorubicin), Decadron (dexamethasone), Baycadron (dexamethasone), Deltasone (prednisone), Dexamethasone Intensol (dexamethasone), Dexpak Taperpak (dexamethasone), and Folotyn are some of the medications used to treat lymphoma (pralatrexate). Prednicot (prednisone), Roferon-A (interferon alfa-2a), Solurex (dexamethasone), Leukeran (chlorambucil), Zema Pak (dexamethasone), Velcade (bortezomib), Sterapred DS (prednisone), Thioplex (thiotepa), Velban (vinblastine), and Trexall are among the other medications (methotrexate).
Market Trends, Drivers, Restraints, and Opportunities
- Increasing incidence of lymphoma worldwide is projected to boost the market growth during the forecast period.
- Increasing initiatives by public as well as private institutes to spread the awareness lymphoma is expected to drive the market growth in the coming years.
- Technological advancements for better diagnosis of lymphoma which in turn results in high cure rate in certain lymphoma is expected to propel the market growth further during the forecast period.
- High cost of treatment for therapies such as immunotherapies, inaccessibility and unavailability suitable payment plans are expected to impede the market growth during the forecast period.
- Increased R&D investments for development of lymphoma treating drugs and technological advancement are expected to offer lucrative opportunities for the market players.
Scope of the Report
The report on the global lymphoma treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
| Attributes | Details |
| Report Title | Lymphoma Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
| Base Year | 2020 |
| Historic Data | 2018–2019 |
| Forecast Period | 2021–2028 |
| Segmentation | Type (Hodgkin Lymphoma and Non-Hodgkin Lymphoma), Drug (Adcetris, Rituxan/MabThera, Imbruvica, Keytruda, Revlimid, and Others) |
| Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
| Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
| Key Players Covered in the Report | Bristol-Myers Squibb Company; Celgene Corporation; Merck & Co., Inc.; F. Hoffmann-La Roche Ltd.; Seattle Genetics, Inc.; Takeda Pharmaceutical Company Ltd.; Johnson & Johnson; Eli Lilly and Company; and Abbott Laboratories |
Market Segment Insights
Non-hodgkin lymphoma segment is expected to account for a key share of the market
Based on type, the lymphoma treatment market is bifurcated into hodgkin lymphoma and non-hodgkin lymphoma. The non-hodgkin lymphoma segment is expected to account for a key share of the market during the forecast period due to presence of major drugs like Revlimid, Rituxan, and Imbruvica.
On the other hand, the hodgkin lymphoma segment is anticipated to expand at a rapid pace during the forecast period due to the label extension of existing medications and the emergence of new therapies for relapsed or refractory hodgkin lymphoma.
Revlimid segment is expected to constitute a key share of the market
Based on drugs, the lymphoma treatment market is segmented into adcetris, opdivo, rituxan, imbruvica, keytruda, revlimid, and others. The revlimid segment is expected to constitute a key share of the market during the forecast period due to increase in the duration of cancer therapies.
On the other hand, the rituxan/mabthera segment is anticipated to expand at a rapid pace during the forecast period owing to increasing usage of this medicine in numerous indications and a high prescription rate in important areas such as the United States and Europe.
North America is anticipated to dominate the market
On the basis of regions, the lymphoma treatment market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market at an impressive CAGR during the forecast period. The regional market growth can be attributed to due to the existence of major players, the availability of novel drugs, the presence of a well-established healthcare system, and substantial R&D spending.
On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years due to rising healthcare expenditure, high growing healthcare needs, increased awareness about treatment options, and availability of effective treatment in emerging countries such as China and South Korea.
Segments
Segments Covered in the ReportThe global lymphoma treatment market has been segmented on the basis of
Type
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
- Adcetris
- Rituxan/MabThera
- Imbruvica
- Keytruda
- Revlimid
- Others
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Bristol-Myers Squibb Company
- Celgene Corporation
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd.
- Seattle Genetics, Inc.
- Takeda Pharmaceutical Company Ltd.
- Johnson & Johnson
- Eli Lilly and Company
- Abbott Laboratories
Competitive Landscape
Key players competing in the lymphoma treatment market are Bristol-Myers Squibb Company; Celgene Corporation; Merck & Co., Inc.; F. Hoffmann-La Roche Ltd.; Seattle Genetics, Inc.; Takeda Pharmaceutical Company Ltd.; Johnson & Johnson; Eli Lilly and Company; and Abbott Laboratories.
Some of the key business strategies employed by companies in the market are mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares. For example, Seattle Genetics' collaborated with Takeda Pharmaceuticals to commercialize Adcetris outside of North America.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Lymphoma Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Lymphoma Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Lymphoma Treatment Market - Supply Chain
4.5. Global Lymphoma Treatment Market Forecast
4.5.1. Lymphoma Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Lymphoma Treatment Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Lymphoma Treatment Market Absolute $ Opportunity
5. Global Lymphoma Treatment Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Lymphoma Treatment Market Size and Volume Forecast by Types
5.3.1. Hodgkin Lymphoma
5.3.2. Non-Hodgkin Lymphoma
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Lymphoma Treatment Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Lymphoma Treatment Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Lymphoma Treatment Demand Share Forecast, 2019-2026
7. North America Lymphoma Treatment Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Lymphoma Treatment Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Lymphoma Treatment Market Size and Volume Forecast by Types
7.4.1. Hodgkin Lymphoma
7.4.2. Non-Hodgkin Lymphoma
7.5. Basis Point Share (BPS) Analysis by Types
7.6. Y-o-Y Growth Projections by Types
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Lymphoma Treatment Demand Share Forecast, 2019-2026
8. Latin America Lymphoma Treatment Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Lymphoma Treatment Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Lymphoma Treatment Market Size and Volume Forecast by Types
8.4.1. Hodgkin Lymphoma
8.4.2. Non-Hodgkin Lymphoma
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Lymphoma Treatment Demand Share Forecast, 2019-2026
9. Europe Lymphoma Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Lymphoma Treatment Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Lymphoma Treatment Market Size and Volume Forecast by Types
9.4.1. Hodgkin Lymphoma
9.4.2. Non-Hodgkin Lymphoma
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Lymphoma Treatment Demand Share Forecast, 2019-2026
10. Asia Pacific Lymphoma Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Lymphoma Treatment Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Lymphoma Treatment Market Size and Volume Forecast by Types
10.4.1. Hodgkin Lymphoma
10.4.2. Non-Hodgkin Lymphoma
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Lymphoma Treatment Demand Share Forecast, 2019-2026
11. Middle East & Africa Lymphoma Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Lymphoma Treatment Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Lymphoma Treatment Market Size and Volume Forecast by Types
11.4.1. Hodgkin Lymphoma
11.4.2. Non-Hodgkin Lymphoma
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Lymphoma Treatment Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Lymphoma Treatment Market: Market Share Analysis
12.2. Lymphoma Treatment Distributors and Customers
12.3. Lymphoma Treatment Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Bristol-Myers Squibb Company
12.4.2. Celgene Corporation
12.4.3. Merck & Co., Inc.
12.4.4. F. Hoffmann-La Roche Ltd.
12.4.5. Seattle Genetics, Inc.
12.4.6. Takeda Pharmaceutical Company Ltd.
12.4.7. Johnson & Johnson
2. Assumptions and Acronyms Used
3. Research Methodology
4. Lymphoma Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Lymphoma Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Lymphoma Treatment Market - Supply Chain
4.5. Global Lymphoma Treatment Market Forecast
4.5.1. Lymphoma Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Lymphoma Treatment Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Lymphoma Treatment Market Absolute $ Opportunity
5. Global Lymphoma Treatment Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Lymphoma Treatment Market Size and Volume Forecast by Types
5.3.1. Hodgkin Lymphoma
5.3.2. Non-Hodgkin Lymphoma
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Lymphoma Treatment Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Lymphoma Treatment Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Lymphoma Treatment Demand Share Forecast, 2019-2026
7. North America Lymphoma Treatment Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Lymphoma Treatment Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Lymphoma Treatment Market Size and Volume Forecast by Types
7.4.1. Hodgkin Lymphoma
7.4.2. Non-Hodgkin Lymphoma
7.5. Basis Point Share (BPS) Analysis by Types
7.6. Y-o-Y Growth Projections by Types
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Lymphoma Treatment Demand Share Forecast, 2019-2026
8. Latin America Lymphoma Treatment Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Lymphoma Treatment Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Lymphoma Treatment Market Size and Volume Forecast by Types
8.4.1. Hodgkin Lymphoma
8.4.2. Non-Hodgkin Lymphoma
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Lymphoma Treatment Demand Share Forecast, 2019-2026
9. Europe Lymphoma Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Lymphoma Treatment Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Lymphoma Treatment Market Size and Volume Forecast by Types
9.4.1. Hodgkin Lymphoma
9.4.2. Non-Hodgkin Lymphoma
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Lymphoma Treatment Demand Share Forecast, 2019-2026
10. Asia Pacific Lymphoma Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Lymphoma Treatment Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Lymphoma Treatment Market Size and Volume Forecast by Types
10.4.1. Hodgkin Lymphoma
10.4.2. Non-Hodgkin Lymphoma
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Lymphoma Treatment Demand Share Forecast, 2019-2026
11. Middle East & Africa Lymphoma Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Lymphoma Treatment Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Lymphoma Treatment Market Size and Volume Forecast by Types
11.4.1. Hodgkin Lymphoma
11.4.2. Non-Hodgkin Lymphoma
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Lymphoma Treatment Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Lymphoma Treatment Market: Market Share Analysis
12.2. Lymphoma Treatment Distributors and Customers
12.3. Lymphoma Treatment Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Bristol-Myers Squibb Company
12.4.2. Celgene Corporation
12.4.3. Merck & Co., Inc.
12.4.4. F. Hoffmann-La Roche Ltd.
12.4.5. Seattle Genetics, Inc.
12.4.6. Takeda Pharmaceutical Company Ltd.
12.4.7. Johnson & Johnson
Our Clients
Related Reports
Some other reports from this category!
